Cabral-Rodríguez GA, Romero-Tafoya JO, García-Estrada C

Language: Spanish
References: 11
Page: 727-732
PDF size: 200.75 Kb.

ABSTRACT

Background: Since the first reports in November 2019, coronavirus 2 has represented a priority health problem causing severe acute respiratory syndrome and other extrapulmonary manifestations, originating a pandemic with millions of deaths. Therefore, vaccines represent the most effective means of controlling the COVID-19 pandemic. Skin reactions to COVID-19 mRNA vaccines have been observed. The objective of this paper is to evaluate the morphology of the cutaneous manifestations and to carry out a review on the current recommendations for their management.
Clinical case: Case 1: A 25-year-old male patient who presented a morbilliform rash after the first dose of the Pfizer vaccine against SARS-CoV-2, which remitted without sequelae at 24 hours. Case 2: A 65-year-old female patient with erythema at the puncture site 10 days after the first dose of the Modern vaccine against SARS-CoV-2 with complete remission on the 4th day after its onset.
Conclusions: Some of the dermatological manifestations to the mRNA COVID-19 vaccines were identified as mimicking the SARS-CoV-2 infection itself. As the administration of vaccines increases, it is essential to recognize and understand their adverse effects.

REFERENCES

1. Sun Q, Fathy R, McMahon D, Freeman EE. COVID-19 vaccinesand the skin. Dermatol Clin 2021; 39 (4) .653-673.https://doi.org/10.1016/j.det.2021.05.016.

2. McMahon D, Amerson E, Rosenbach M, Lipoff J, et al.Cutaneous reactions reported after Moderna and PfizerCOVID-19 vaccination: A registry-based study of 414 cases.J Am Acad Dermatol 2021; 85 (1):46-55. https://doi.org/10.1016/j.jaad.2021.03.092

3. Cheung A, Perrett K, Immunisation and allergy in childrenand adults: A case-based approach. Australian J GeneralPract 2020; 49 (10): 637-643. https://doi.org/10.31128/AJGP-07-20-5547.

4. Cdc.gov. 2021. Interim Clinical Considerations for Use ofCOVID-19 Vaccines | CDC. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

5. Castells M, Phillips E. Maintaining safety with SARS-CoV-2vaccines. N Engl J Med 2021; 384 (7): 643-649. https://doi.org/10.1056/NEJMra2035343.

6. Jedlowski P, Jedlowski M. Morbilliform rash after administrationof Pfizer-BioNTech COVID-19 mRNA vaccine.Dermatol Online J 2021; 27 (1). https://doi.org/10.5070/D3271052044.

7. Corbeddu M, Diociaiuti A, Vinci M, Santoro A, et al. Transientcutaneous manifestations after administration ofPfizer‐BioNTech COVID‐19 vaccine: an Italian single‐centrecase series. J Eur Acad Dermatol Venereol 2021, 35 (8).https://doi.org/10.1111/jdv.17268.

8. Cook I. Sex differences in injection site reactions withhuman vaccines. Human Vaccines 2009; 5 (7): 441-449.https://doi.org/10.4161/hv.8476.

9. Johnston M, Galan A, Watsky K, Little A. Delayed localizedhypersensitivity reactions to the Moderna COVID-19 vaccine.JAMA Dermatology 2021; 157 (6): 716. https://doi.org/10.1001/jamadermatol.2021.1214.

10. Baden L, El Sahly H, Essink B, Kotloff K, et al. Efficacy andsafety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl JMed 2021; 384 (5): 403-416. https://doi.org/10.1056/NEJMoa2035389.

11. Ring J, Worm M, Wollenberg A, Thyssen JP, et al. Risk ofsevere allergic reactions to COVID‐19 vaccines amongpatients with allergic skin diseases – practical recommendations.A position statement of ETFAD with externalexperts. J Eur Acad Dermatol Venereol 2021; 35 (6). https://doi.org/10.1111/jdv.17237.